Outcomes
PTSD
Assessments occurred at 6 weeks, 13 weeks (end of weekly phase or waiting list), 26 weeks (end of booster phase), 39 weeks, and 65 weeks after randomisation. The primary outcome was PTSD symptom severity on the self-reported PCL-5 at 13 weeks.Secondary measures of other outcomes included the Patient Health Questionnaire (PHQ-9)The IAPT Patient Experience Questionnaire